Sigumir®
Distribution of patients by diagnosis, sex and age. Table 1
Diagnosis Age Male Female Total
Control Primary Control Primary Control Primary
Group Group Group Group Group Group
Knee osteoarthritis 59-78 6 7 3 3 9 10
Osteochondritis of the spine 45-69 7 6 8 9 15 15
Osteoporosis 45-65 - - 7 8 7 8
Total: 13 13 11 12 31 33
RESEARCH METHODS
To assess the effectiveness of the use of SIGUMIR®, we analyzed the dynamics of patients’ complaints
and objective indicators: general clinical examination of blood and urine, biochemical blood test, and
X-ray.
RESEARCH RESULTS
It should be noted that the radiology symptoms of degenerative-dystrophic diseases of the joints and the
spine are not only objective diagnostic criteria for the stage of development of the pathological process
but also have a great prognostic value in drug therapy.
It was found that the use of SIGUMIR® in patients with osteoarthritis of the knee joints contributed
to a decrease in pain syndrome and an increase in joint mobility in 68.5% of cases. At the same time,
pain symptoms disappeared almost entirely at the radiologically determined initial stages of the disease:
narrowing of the joint space between the patella and the thigh, lateral osteophytes of the patella, and
femoral condyle. No significant dynamics of radiological symptoms were observed during this period.
In patients in the advanced stage of arthrosis, a similar but less pronounced dynamics of subjective
indicators was observed. Since this stage of the disease was diagnosed in persons of the older age group,
such subjective sensations were characterized as very favorable.
In patients with osteochondrosis of the lumbar spine, the use of SIGUMIR® against the background of
complex therapy helped reduce pain in 53.7% of cases. A progressive course of the disease with age,
accompanied by characteristic X-ray symptoms (narrowing of the lumen between adjacent vertebral
bodies due to flattening of degeneratively altered intervertebral discs; the formation of anterior and
posterior osteophytes of the vertebral bodies, the presence of arthritic changes in the posterior and
lateral intervertebral joints in the form of narrowing of the crevices, unevenness development of
osteophytes along the edges of the articular ends; changes in the configuration of the intervertebral
foramen), contributed to the development of spondylosis and spondyloarthrosis and the formation of
neurodystrophic and neurovascular syndromes. These dynamics were most typical for middle-aged
people. In these cases, long-term (at least 45-60 days) use of SIGUMIR® smoothed out pain symptoms
arising from stress on the spine and lower extremities and increased the spine’s mobility.
In patients with osteoporosis, with prolonged use of the drug, the stabilization of metabolic processes in
the bone tissue was noted: the number of characteristic fractures decreased, the process of restoration
of the function of the musculoskeletal system was significantly accelerated, and the time spent in the
hospital decreased.
All patients showed a significant smoothing of the main symptoms of this group of diseases, characterized
by substantial conservatism.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.